AmpliPhi Biosciences Announces Presentations of Clinical and Preclinical Data from Studies with its Bacteriophage Technology at Two Scientific Conferences
CATEGORY:
Featured
Tuesday, April 4, 2017 6:50 am EDT – link here
SAN DIEGO
EmailPDFPrintRSS
PUBLIC COMPANY INFORMATION:
NYSEMKT:
APHB
“AmpliPhi and our partners have produced promising clinical and nonclinical data demonstrating AmpliPhi’s phage cocktails are safe and active against a broad footprint of isolates, including those that are multidrug-resistant”
SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces that data from its investigational bacteriophage programs, AB-SA01 targeting Staphylococcus aureus (S. aureus) infections and AB-PA01 targeting Pseudomonas aeruginosa (P. aeruginosa)infections, are featured in presentations at two scientific conferences:
|
The 2017 Australian Society of Otolaryngology Head and Neck Surgery Meeting (March 23-26, Adelaide, Australia) |
|||||
|
1. |
Oral presentation: A phase 1 clinical trial to evaluate the safety, tolerability and preliminary effectiveness of AB-SA01 in patients with chronic rhinosinusitis associated with Staphylococcus aureus infection |
||||
| Date: March 25, 2017 | |||||
| Presenter: Dr. Mian Ooi, University of Adelaide and The Queen Elizabeth Hospital | |||||
|
Results of the Phase 1 study evaluating AB-SA01 in chronic rhinosinusitis (CRS) patients with an active S. aureus infection, including safety and preliminary evaluation of efficacy: |
|||||
|
• |
AB-SA01 was safe and well tolerated |
||||
|
• |
S. aureus bacterial load decreased in all nine patients treated with AB-SA01. Two of six patients treated for 14 days exhibited complete eradication of S. aureus bacterial load |
||||
|
• |
Preliminary three-month follow-up data demonstrated sustained improvement of symptoms |
||||
|
2. |
Poster: Bacteriophage therapy for treating Pseudomonas aeruginosa infections in chronic rhinosinusitis |
||||
| Date: March 24, 2017 | |||||
| Presenter: Dr. Stephanie Fong, University of Adelaide and The Queen Elizabeth Hospital | |||||
|
AB-PA01 demonstrated a broad footprint of activity in P. aeruginosa clinical isolates in vitro, including activity against 85% of the 40 CRS isolates tested. For both cystic fibrosis and CRS clinical isolates, AB-PA01 exhibits a broad spectrum of activity and the ability to penetrate and reduce biofilms. CRS is highly prevalent in cystic fibrosis patients and can contribute to the deterioration of lung function. |
|||||
|
Solutions for Drug-Resistant Infections Meeting (April 3-5, Brisbane, Australia) |
|||||
|
3. |
Oral presentation: Clinical bacteriophage therapy in the 21 st century |
||||
| Date: April 4, 2017 | |||||
| Presenter: Dr. Sandra Morales, Vice President of Research, AmpliPhi Biosciences | |||||
| Results from preclinical and clinical trials supporting the potential for bacteriophage therapy to address the rising-tide of antibiotic-resistant infections and the combined use of phage and antibiotics to combat antibiotic-resistant bacteria with the added potential of resensitizing bacteria to antibiotics to which the bacteria were initially resistant. | |||||
|
4. |
Oral presentation: A Phase 1 study to evaluate the safety, tolerability and preliminary effectiveness of AB-SA01 in patients with chronic rhinosinusitis associated with Staphylococcus aureus infection |
||||
| Date: April 4, 2017 | |||||
| Presenter: Dr. Sandra Morales, Vice President of Research, AmpliPhi Biosciences | |||||
|
Results of the Phase 1 study showing that AB-SA01 in CRS patients with an active S. aureusinfection was safe and well tolerated and decreased S. aureus bacterial load in all nine patients treated with AB-SA01. |
|||||
“AmpliPhi and our partners have produced promising clinical and nonclinical data demonstrating AmpliPhi’s phage cocktails are safe and active against a broad footprint of isolates, including those that are multidrug-resistant,” said M. Scott Salka, CEO of AmpliPhi Biosciences. “We are delighted these results are being shared with the scientific community.”
About Bacteriophages
Bacteriophages, or more simply “phages,” are the natural predators of bacteria and are the most abundant life form on earth. Over eons, phages have evolved an incredible diversity of specialist strains that typically prey upon just one strain of bacteria, enabling phage therapies to precisely target pathogenic bacteria while sparing the beneficial microbiota. Phages can infect and kill bacteria, whether they are antibiotic-resistant or not, and even when they have formed protective biofilms.
About AmpliPhi Biosciences
AmpliPhi Biosciences Corporation is a biotechnology company pioneering the development and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. AmpliPhi’s product development programs target infections that are often resistant to some or all existing antibiotic treatments. AmpliPhi has reported final results from two Phase 1 clinical trials of AB-SA01, one for the treatment of S. aureus in CRS patients and one to evaluate the safety of AB-SA01 when administered topically to the intact skin of healthy adults. AmpliPhi is also developing bacteriophage therapeutics targeting P. aeruginosa and Clostridium difficile (C. difficile) in collaboration with a number of leading research organizations. For more information visit www.ampliphibio.com.
Forward Looking Statements
Statements in this press release that are not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements about the potential use of bacteriophages to treat bacterial infections, including infections that do not respond to antibiotics, the potential benefits of phage therapy, including the ability to resensitize drug-resistant bacteria to antibiotics to which the bacteria were initially resistant, and AmpliPhi’s development of bacteriophage-based therapies. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “will,” “may,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. Among the factors that could cause actual results to differ materially from those indicated in these forward-looking statements are risks and uncertainties associated with AmpliPhi’s business and financial condition and the other risks and uncertainties described in AmpliPhi’s Annual Report on Form 10-K for the year ended December 31, 2016, as filed with the SEC, and other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and AmpliPhi undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
CONTACT:
At the Company:
AmpliPhi Biosciences
Matthew Dansey
(858) 800-4869
md@ampliphibio.com
or
Investor Relations:
LHA
Jody Cain
(310) 691-7100
jcain@lhai.com